Gabriel Berberi BSc , Mahan Maazi MEng , Connor Prosty MD , Eric P. McMullen MD , Michael Fein MD, MSc , Hermenio Lima MD , Elvis Martinez-Jaramillo MD, PhD , Moshe Ben-Shoshan MD, MSc , Farhad Pourpanah PhD , Elena Netchiporouk MD, MSc
{"title":"Health-Related Quality of Life in Chronic Urticaria: A Systematic Review and Meta-Analysis","authors":"Gabriel Berberi BSc , Mahan Maazi MEng , Connor Prosty MD , Eric P. McMullen MD , Michael Fein MD, MSc , Hermenio Lima MD , Elvis Martinez-Jaramillo MD, PhD , Moshe Ben-Shoshan MD, MSc , Farhad Pourpanah PhD , Elena Netchiporouk MD, MSc","doi":"10.1016/j.jaip.2025.03.049","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Chronic urticaria<span> (CU), including chronic spontaneous urticaria<span><span> (CSU) and chronic inducible urticaria (CIndU), significantly affect patients’ health-related quality of life (HRQOL). To date, no </span>systematic reviews or meta-analyses have summarized the HRQOL tools used in CU and the magnitude of HRQOL impact in CU.</span></span></div></div><div><h3>Objective</h3><div>To determine the HRQOL tools used in CU, the burden of CU regarding HRQOL in adults and children, and whether CU subtypes differentially affect HRQOL.</div></div><div><h3>Methods</h3><div>We searched MEDLINE, Embase, Web of Science, Cochrane, CINAHL, and PsycINFO from inception to August 20, 2023 for original articles including populations of adult or pediatric<span> patients with CU or any of its subtypes in which HRQOL was reported using any quality-of-life instrument. We conducted a series of meta-analyses to pool and compare data on HRQOL outcomes by CU subtype, primarily using the Dermatology Life Quality Index.</span></div></div><div><h3>Results</h3><div>We identified 123 publications reporting on 23,508 unique patients with CU and/or its subtypes. The meta-analysis revealed a moderate to large impact of CU and its subtypes on HRQOL. In adults, pooled mean Dermatology Life Quality Index score was 8.9 (95% CI, 7.7-10.1) for CU, 11.0 (95% CI, 9.3-12.7) for CSU, 8.3 (95% CI, 6.8-9.8) for CIndU, and 10.0 (95% CI, 7.7-12.4) for concomitant CSU/CIndU. In children with CSU, mean Children Dermatology Life Quality Index score was 6.9 (95% CI, 1.9-12.0). The analysis revealed high heterogeneity, likely owing to differences in patient population and study design.</div></div><div><h3>Conclusions</h3><div>Chronic urticaria and its subtypes significantly impair HRQOL. The clinical implication of the differences among CU subtypes needs to be further explored, along with additional research in pediatric populations.</div></div>","PeriodicalId":51323,"journal":{"name":"Journal of Allergy and Clinical Immunology-In Practice","volume":"13 9","pages":"Pages 2317-2328"},"PeriodicalIF":6.6000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology-In Practice","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2213219825003149","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background
Chronic urticaria (CU), including chronic spontaneous urticaria (CSU) and chronic inducible urticaria (CIndU), significantly affect patients’ health-related quality of life (HRQOL). To date, no systematic reviews or meta-analyses have summarized the HRQOL tools used in CU and the magnitude of HRQOL impact in CU.
Objective
To determine the HRQOL tools used in CU, the burden of CU regarding HRQOL in adults and children, and whether CU subtypes differentially affect HRQOL.
Methods
We searched MEDLINE, Embase, Web of Science, Cochrane, CINAHL, and PsycINFO from inception to August 20, 2023 for original articles including populations of adult or pediatric patients with CU or any of its subtypes in which HRQOL was reported using any quality-of-life instrument. We conducted a series of meta-analyses to pool and compare data on HRQOL outcomes by CU subtype, primarily using the Dermatology Life Quality Index.
Results
We identified 123 publications reporting on 23,508 unique patients with CU and/or its subtypes. The meta-analysis revealed a moderate to large impact of CU and its subtypes on HRQOL. In adults, pooled mean Dermatology Life Quality Index score was 8.9 (95% CI, 7.7-10.1) for CU, 11.0 (95% CI, 9.3-12.7) for CSU, 8.3 (95% CI, 6.8-9.8) for CIndU, and 10.0 (95% CI, 7.7-12.4) for concomitant CSU/CIndU. In children with CSU, mean Children Dermatology Life Quality Index score was 6.9 (95% CI, 1.9-12.0). The analysis revealed high heterogeneity, likely owing to differences in patient population and study design.
Conclusions
Chronic urticaria and its subtypes significantly impair HRQOL. The clinical implication of the differences among CU subtypes needs to be further explored, along with additional research in pediatric populations.
期刊介绍:
JACI: In Practice is an official publication of the American Academy of Allergy, Asthma & Immunology (AAAAI). It is a companion title to The Journal of Allergy and Clinical Immunology, and it aims to provide timely clinical papers, case reports, and management recommendations to clinical allergists and other physicians dealing with allergic and immunologic diseases in their practice. The mission of JACI: In Practice is to offer valid and impactful information that supports evidence-based clinical decisions in the diagnosis and management of asthma, allergies, immunologic conditions, and related diseases.
This journal publishes articles on various conditions treated by allergist-immunologists, including food allergy, respiratory disorders (such as asthma, rhinitis, nasal polyps, sinusitis, cough, ABPA, and hypersensitivity pneumonitis), drug allergy, insect sting allergy, anaphylaxis, dermatologic disorders (such as atopic dermatitis, contact dermatitis, urticaria, angioedema, and HAE), immunodeficiency, autoinflammatory syndromes, eosinophilic disorders, and mast cell disorders.
The focus of the journal is on providing cutting-edge clinical information that practitioners can use in their everyday practice or to acquire new knowledge and skills for the benefit of their patients. However, mechanistic or translational studies without immediate or near future clinical relevance, as well as animal studies, are not within the scope of the journal.